Why Hibernaid? Hibernaid In the News

Contact us for more information

Over one million Americans suffer from acute brain injury (ABI) each year.

ABI occurs after such incidents as stroke, traumatic brain injury or cardiac arrest.

Over 70% will suffer some degree of permanent brain damage, and emergency medical physicians remain virtually helpless to prevent this tragedy.

Hypothermia is an accepted and effective intervention to save vital organs from reperfusion injury and to reduce brain damage.

However, hypothermia remains an underutilized treatment as current methods of lowering body temperature – for example, mechanical cooling devices and intravascular catheters – are difficult to administer and control, typically require complex procedural and ancillary support mechanisms, and are associated with a broad range of serious side effects and other adverse consequences of the treatment application itself.

These limitations have led to significant underutilization of this potentially important intervention. It has been estimated that less than 5% of eligible post-cardiac arrest patients who might benefit from hypothermia are actually treated.

Hibernaid plans to revolutionize the regulated hypothermia industry by providing a better alternative to current hypothermia methods in the form of the first pharmaceutical product to safely and more effectively lower body temperature to treat acute brain injuries as well as injuries to other vital organs and to improve survival rates among affected patients.